Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva
Executive Summary
The indication for Ultram (tramadol) cannot be divided into chronic versus acute pain to justify omission of patent-protected titration dosing from generic labeling, Johnson & Johnson told FDA